Modern cancer therapies often rely on the specific targeting of mutated proteins by small molecules that interfere with their function. However, some of these proteins which drive cancer are difficult to target directly. To get round this problem, scientists have tapped into the ubiquitin-proteasome system (UPS) which controls the stability of client proteins. Their findings are published in Nature today (18th October 2017).
FDA approved drugs “VelcadeTM” or “CarfilzomibTM”target the proteasome directly and are already used in the clinic to treat patients with Multiple Myeloma and Mantle Cell Lymphoma.
A multi-disciplinary research team from the MRC Laboratory of Molecular Biology, the Universities of Oxford (TDI Kessler group), Liverpool, Cancer Research UK and Forma Therapeutics has focused on another component of the system, USP7. This controls the stability of a protein called p53 that is lost in many cancer types. p53 is critical for controlling cell growth. USP7 inhibition elevates levels of p53 and interferes with cancer cell proliferation. Chemists at Forma obtained potent and selective inhibitors against USP7, which are supported by elegant structural work at atomic resolution, detailing how the drug binds to its target.
USP7 is a member of a family of proteins called deubiquitylating enzymes (DUBs), and it has been unclear whether it would be possible to design drugs that are selective for just one member of the DUB family.“We show not only that this is possible, but our structures provide a detailed understanding of how this is achieved“ says Dr. Andrew Turnbull of CRUK’s Therapeutic Discovery Labs, one of the lead authors of the study. Extending the approach to other family members will open up ways to target other previously “undruggable”proteins which drive cancer, or in fact other chronic diseases such as neurodegeneration and immunological disorders.